Evidence map›Paper›PMID 30190447›Full record

ArticleJournal of biomedical research2018

Association between Pri-miR-34b/c rs4938723 polymorphism and bladder cancer risk.

Mohammad Hashemi, Vahed Hasanpour, Hiva Danesh, Fatemeh Bizhani, Behzad Narouie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammad HashemiCellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Sistan and Baluchistan 98167-43181, Iran.
Vahed HasanpourStudent Research Committee, Zahedan University of Medical Sciences, Zahedan, Sistan and Baluchistan 98167-43181, Iran.
Hiva DaneshDepartment of Clinical Biochemistry, Zahedan University of Medical Sciences, Zahedan, Sistan and Baluchistan 98167-43181, Iran.
Fatemeh BizhaniDepartment of Clinical Biochemistry, Zahedan University of Medical Sciences, Zahedan, Sistan and Baluchistan 98167-43181, Iran.
Behzad NarouieUrology and Nephrology Research Center, Department of Urology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Tehran 198396-3113, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several studies examined the impact of miR-34b/c rs4938723 polymorphism and cancer risk, but the findings are inconsistent. However, no study has been conducted to inspect the impact of miR-34b/c polymorphism on bladder cancer. This study aimed to assess possible association between rs4938723 polymorphism and bladder cancer risk. This case-control study was done on 136 pathologically proven bladder cancer patients and 144 controls. Genotyping of Pri-miR-34b/c rs4938723 polymorphism was achieved by using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. Our findings did not show any statistically significant differences in genotype and allele frequencies between bladder cancer and controls. Larger sample sizes with diverse ethnicities are required to validate our findings.

Identifiers

PMID30190447
PMCPMC6352879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.